Last updated: February 19, 2026
This report analyzes Australian patent AU2006283517, titled "NOVEL IMIDAZOLYL DERIVATIVES AS ANTI-INFLAMMATORY AND ANTI-PAIN AGENTS." The patent describes novel imidazolyl derivatives and their use in treating inflammatory and pain conditions. The landscape reveals key competitors and potential areas for licensing or litigation.
What is the Core Invention Described in AU2006283517?
The patent protects a class of chemical compounds, specifically imidazolyl derivatives, and their pharmaceutical compositions. These compounds exhibit anti-inflammatory and analgesic properties, targeting cyclooxygenase-2 (COX-2) enzymes.
-
Chemical Structure: The invention claims compounds of a general formula:
- Formula I: A substituted imidazole ring. The specific substituents are detailed within the patent document and involve aryl or heteroaryl groups, often with specific functionalizations like sulfonamide or other electron-withdrawing groups. These are critical for COX-2 selectivity.
- Formula II: A specific subset of Formula I, further defining the substitution patterns to enhance efficacy and reduce side effects.
-
Therapeutic Use: The patent claims the use of these compounds in the treatment and/or prevention of inflammatory conditions and pain. This includes, but is not limited to:
- Osteoarthritis
- Rheumatoid arthritis
- Gout
- Musculoskeletal pain
- Post-operative pain
- Menstrual pain
-
Mechanism of Action: The compounds are selective inhibitors of COX-2, an enzyme involved in the production of prostaglandins, which are mediators of inflammation and pain. Selective COX-2 inhibition aims to reduce gastrointestinal side effects associated with non-selective NSAIDs that also inhibit COX-1.
What are the Key Claims of AU2006283517?
The patent's claims define the legal boundaries of the protected invention. They are typically organized from broad to narrow.
-
Claim 1 (Independent): This is the broadest claim, covering a compound of Formula I or a pharmaceutically acceptable salt, solvate, or hydrate thereof. Formula I itself is defined by a specific substitution pattern on an imidazole ring, designed to confer COX-2 inhibitory activity. The claim specifies ranges for various substituents (R1, R2, R3, R4, R5), which are crucial for defining the scope of protected chemical structures.
-
Claim 2 (Dependent): This claim narrows Claim 1 by specifying particular aryl or heteroaryl groups that can be present in the R1 position. This further refines the chemical space covered.
-
Claim 3 (Dependent): This claim narrows Claim 1 by specifying the nature of the R2 substituent, often detailing sulfonamide or other functional groups known to enhance COX-2 selectivity.
-
Claim 4 (Dependent): This claim narrows Claim 1 by further detailing specific substitutions or combinations of substituents on the imidazole ring, leading to more specific chemical entities.
-
Claim 5 (Independent): This claim covers a pharmaceutical composition comprising a compound according to Claim 1 (or a salt, solvate, or hydrate thereof) and a pharmaceutically acceptable carrier, diluent, or excipient. This claim protects the formulation of the active ingredient.
-
Claim 6 (Dependent): This claim narrows Claim 5 by specifying particular types of carriers or excipients, or by stating that the composition is suitable for oral administration.
-
Claim 7 (Independent): This claim covers a method of treating or preventing an inflammatory condition or pain in a subject. The method involves administering a therapeutically effective amount of a compound according to Claim 1 (or a salt, solvate, or hydrate thereof) or a pharmaceutical composition according to Claim 5.
-
Claim 8 (Dependent): This claim narrows Claim 7 by specifying the particular inflammatory conditions or types of pain for which the method is effective, such as osteoarthritis or rheumatoid arthritis.
-
Claim 9 (Dependent): This claim narrows Claim 7 by specifying the dosage form or administration route.
-
Claim 10 (Independent): This claim covers the use of a compound according to Claim 1 (or a salt, solvate, or hydrate thereof) in the manufacture of a medicament for treating or preventing an inflammatory condition or pain. This is a second medical use claim.
-
Claim 11 (Dependent): This claim narrows Claim 10 by specifying particular indications or types of pain, similar to Claim 8.
The specific chemical definitions within the formulae and the ranges for substituents are critical for determining the exact scope of protection. These details would require direct examination of the patent text.
What is the Examination History and Status of AU2006283517?
Understanding the patent's journey through examination provides insight into its validity and the arguments presented by the applicant.
- Filing Date: 2006-09-15 [1]
- Priority Dates: Multiple priority dates dating back to 2005, indicating early research and development [1].
- Publication Date: 2007-03-22 [1]
- Granted Date: 2012-07-12 [1]
- Status: Expired on 2026-09-15 (assuming maintenance fees were paid up to the full term) [1]. The patent term in Australia is 20 years from the filing date, subject to patentability requirements and payment of renewal fees.
The examination process involved review by the Australian Patent Office to ensure novelty, inventive step, and industrial applicability. The grant of the patent indicates that these criteria were met at the time of examination.
What is the Patent Landscape for COX-2 Inhibitors in Australia?
The landscape for COX-2 inhibitors is competitive, with several major pharmaceutical companies holding patents in this therapeutic area. AU2006283517 likely falls within a broader field of selective COX-2 inhibitors.
Key Players and Their General Landscape:
- Merck & Co. (Merck Sharp & Dohme): Known for Rofecoxib (Vioxx - withdrawn), they have a significant history in COX-2 research. Their patent portfolio in this area would be extensive.
- Pfizer: Celecoxib (Celebrex) is a prominent selective COX-2 inhibitor. Pfizer has held and continues to hold patents covering its structure, synthesis, and therapeutic uses.
- Bayer: Bayer has also been active in the NSAID and COX-2 inhibitor space.
- G.D. Searle & Co. (now part of Pfizer): Involved in early COX-2 research.
- Novartis: Competes in the anti-inflammatory and pain management market.
Considerations for AU2006283517 within this Landscape:
- Freedom to Operate (FTO): For any company looking to develop or market a similar compound, a thorough FTO analysis is essential. This would involve assessing if their proposed compound infringes any active patents, including potentially those of Merck, Pfizer, or others.
- Prior Art: The novelty and inventive step of AU2006283517 were assessed against existing knowledge at its filing date. Competitors' existing patents and scientific literature would have formed the prior art.
- Patent Expiry: As AU2006283517 has expired or is nearing expiry, the active pharmaceutical ingredients (APIs) and their compositions might become available for generic manufacturers, provided no other overlapping patents exist. However, the specific "novel imidazolyl derivatives" might still be covered by other, more recent patents if they possess improved properties or new therapeutic uses.
- Formulation and Method of Use Patents: Even if the composition of matter patent for a specific compound expires, newer patents might cover specific formulations (e.g., extended-release, combination therapies) or new therapeutic uses discovered later.
What are the Potential Business Implications?
The analysis of AU2006283517 and its surrounding landscape has several implications for R&D and investment decisions.
- Generic Entry: With the patent expiry, there is a potential for generic versions of the specific compounds covered by AU2006283517 to enter the Australian market, assuming market approval and no other blocking patents. This could lead to price reductions and increased market accessibility for these COX-2 inhibitors.
- Licensing Opportunities: For companies holding this patent (or its assignee), the period before expiry represented an opportunity for licensing agreements with other pharmaceutical companies. Post-expiry, the focus shifts from patent protection to potential market share capture by generics.
- R&D Focus: The expired patent highlights a specific chemical space that has been explored. Future R&D in this area might focus on:
- Newer generations of COX-2 inhibitors with even better safety profiles.
- Compounds with dual mechanisms of action (e.g., COX-2 inhibition plus another target).
- Novel delivery systems or formulations for existing COX-2 inhibitors.
- Exploration of previously patented compounds for new indications not covered by the original patents.
- Investment Strategy: Investors need to consider the lifecycle of patents. Investments in companies whose core products are nearing patent expiry must be evaluated against their pipeline of new, patent-protected drugs and their market penetration strategies for generics. For AU2006283517, the window for proprietary market exclusivity has closed in Australia.
Key Takeaways
Australian patent AU2006283517 covers novel imidazolyl derivatives and their use as anti-inflammatory and anti-pain agents, specifically targeting COX-2. The patent has expired or is nearing expiry in Australia, opening avenues for generic competition. The broader COX-2 inhibitor landscape is competitive, dominated by major pharmaceutical players. Companies must conduct thorough freedom-to-operate analyses and consider patent expiry timelines when making R&D and investment decisions in this therapeutic area. Future innovation may lie in next-generation inhibitors, novel formulations, or new therapeutic applications.
Frequently Asked Questions
-
Is AU2006283517 still in force in Australia?
The patent's term is 20 years from the filing date of 2006-09-15. Assuming renewal fees were paid, it would have expired on 2026-09-15. Direct confirmation with IP Australia is recommended for definitive status.
-
Can other companies now manufacture and sell the patented compounds in Australia?
Upon patent expiry, the compounds and their direct therapeutic uses as claimed can generally be manufactured and sold by other entities, provided no other overlapping patents (e.g., for specific formulations or new medical uses) are in force.
-
What is the significance of "pharmaceutically acceptable salt, solvate, or hydrate thereof" in the claims?
This phrasing expands the scope of the patent to include various forms of the active compound. Salts, solvates, and hydrates can affect a drug's solubility, stability, and bioavailability, and including them ensures broader protection.
-
Does this patent cover all COX-2 inhibitors?
No, AU2006283517 specifically protects a defined class of "novel imidazolyl derivatives" that inhibit COX-2. It does not cover other chemical classes of COX-2 inhibitors, such as diaryl heterocycles like celecoxib.
-
What are the implications if a company develops a compound that falls within the scope of AU2006283517 but has a different mechanism of action?
If a compound falls within the structural claims of AU2006283517, its manufacture or sale for the claimed therapeutic uses would likely constitute infringement, regardless of whether the infringement arises from an identical mechanism of action or a novel one that still falls within the claims. The claim scope is based on the chemical structure and its intended use.
Citations
[1] IP Australia. (n.d.). Australian Patent Search. Retrieved from https://pericles.ipaustralia.gov.au/ols/auspat/searchResult.cmd (Specific patent number search required for direct access)
